Athersys, Inc.

ATHXQ

US04744L2051

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:40:26 2024-07-02 EDT			5-day change	1st Jan Change
0.0033 ^USD	0.00%		+6.45%	-83.50%

06-16	Motion for Case Conversion Filed by Athersys, Inc.	CI
04-11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ

Athersys, Inc. Announces Resignation of Ivor Macleod as Chief Financial Officer, Effective June 30, 2022

June 02, 2022 at 04:05 pm

Athersys, Inc. announced that Mr. Ivor Macleod, Chief Financial Officer, will be leaving the Company on June 30, 2022.

Latest news about Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.	06-16	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	04-11	DJ
Athersys, Inc. Announces Board Changes	04-05	CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP	04-04	MT
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	04-02	CI
Motion for Asset Sale Approved for Athersys, Inc.	03-27	CI
Notice of Cancellation of Auction Filed by Athersys, Inc.	02-29	CI
Final DIP Financing Approved for Athersys, Inc.	02-12	CI
Bidding Procedure Approved for Athersys, Inc.	02-12	CI
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal	01-17	MT
Interim DIP Financing Approved for Athersys, Inc.	01-12	CI
Motion for Joint Administration Approved for Athersys, Inc.	01-11	CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy	01-10	MT
Motion for Asset Sale Filed by Athersys, Inc.	01-05	CI
Motion for Joint Administration Filed by Athersys, Inc.	01-05	CI
Athersys, Inc. Filed for Bankruptcy	01-04	CI
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million.	01-04	CI
Athersys, Inc. Announces Termination of Maia Hansen as Chief Operating Officer, Effective from December 31, 2023	12-22	CI
Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023	12-22	CI
Athersys, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	11-16	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	11-14	DJ
Athersys Delisted from Nasdaq Risks Bankruptcy; Healios Remains Committed to Drug Development	23-10-20	MT
Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index	23-10-20	CI
Athersys, Inc.(OTCPK:ATHX) dropped from NASDAQ Composite Index	23-10-17	CI

Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ATHERSYS, INC.	-83.50%	204K
VERTEX PHARMACEUTICALS INCORPORATED	+16.23%	122B
REGENERON PHARMACEUTICALS, INC.	+17.35%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.92%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-19.83%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+60.01%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.96%	14.1B

Bio Therapeutic Drugs

Athersys, Inc.

Equities

ATHXQ

US04744L2051

Biotechnology & Medical Research

Athersys, Inc. Announces Resignation of Ivor Macleod as Chief Financial Officer, Effective June 30, 2022

Latest news about Athersys, Inc.

Chart Athersys, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs